Effect of TRPV4 Antagonist GSK2798745 on Chlorine Gas-Induced Acute Lung Injury in a Swine Model
-
Published:2024-04-02
Issue:7
Volume:25
Page:3949
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Vermillion Meghan S.1, Saari Nathan1, Bray Mathieu2, Nelson Andrew M.1, Bullard Robert L.1, Rudolph Karin1, Gigliotti Andrew P.1, Brendler Jeffrey1, Jantzi Jacob1, Kuehl Philip J.1ORCID, McDonald Jacob D.1, Burgert Mark E.2, Weber Waylon1, Sucoloski Scott2, Behm David J.2
Affiliation:
1. Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA 2. GSK, Collegeville, PA 19426, USA
Abstract
As a regulator of alveolo-capillary barrier integrity, Transient Receptor Potential Vanilloid 4 (TRPV4) antagonism represents a promising strategy for reducing pulmonary edema secondary to chemical inhalation. In an experimental model of acute lung injury induced by exposure of anesthetized swine to chlorine gas by mechanical ventilation, the dose-dependent effects of TRPV4 inhibitor GSK2798745 were evaluated. Pulmonary function and oxygenation were measured hourly; airway responsiveness, wet-to-dry lung weight ratios, airway inflammation, and histopathology were assessed 24 h post-exposure. Exposure to 240 parts per million (ppm) chlorine gas for ≥50 min resulted in acute lung injury characterized by sustained changes in the ratio of partial pressure of oxygen in arterial blood to the fraction of inspiratory oxygen concentration (PaO2/FiO2), oxygenation index, peak inspiratory pressure, dynamic lung compliance, and respiratory system resistance over 24 h. Chlorine exposure also heightened airway response to methacholine and increased wet-to-dry lung weight ratios at 24 h. Following 55-min chlorine gas exposure, GSK2798745 marginally improved PaO2/FiO2, but did not impact lung function, airway responsiveness, wet-to-dry lung weight ratios, airway inflammation, or histopathology. In summary, in this swine model of chlorine gas-induced acute lung injury, GSK2798745 did not demonstrate a clinically relevant improvement of key disease endpoints.
Funder
Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Services
Reference30 articles.
1. Chlorine gas inhalation: Human clinical evidence of toxicity and experience in animal models;White;Proc. Am. Thorac. Soc.,2010 2. Emergency management of chlorine gas exposure—A systematic review;Despreaux;Clin. Toxicol.,2019 3. The effect of nebulized NaHCO3 treatment on “RADS” due to chlorine gas inhalation;Aslan;Inhal. Toxicol.,2006 4. TRPV4: An exciting new target to promote alveolocapillary barrier function;Morty;Am. J. Physiol. Lung Cell Mol. Physiol.,2014 5. Pairet, N., Mang, S., Fois, G., Keck, M., Kuhnbach, M., Gindele, J., Frick, M., Dietl, P., and Lamb, D.J. (2018). TRPV4 inhibition attenuates stretch-induced inflammatory cellular responses and lung barrier dysfunction during mechanical ventilation. PLoS ONE, 13.
|
|